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INTRODUCTION
Diabetes Mellitus belongs to a group of metabolic
disorders characterized by chronic elevation of blood glucose
concentration (hyperglycemia), as a consequence in the
failure of insulin secretion, in its action or both (Kahn &
Rosseti, 1998). Type 2 Diabetes Mellitus (T2DM) is the most
common form of diabetes. This variant generally does not
present autoimmune destruction of pancreatic beta cells,
therefore the lack of insulin characteristic of type I diabetes
mellitus is not a hallmark of T2DM (ADA, 2007; 2009).
Several pathological processes are involved in the onset of
this disease, being one of the first in apparition, the reduction
of insulin sensitivity in target tissues of this hormone, like
skeletal muscle, liver and adipose tissue (Saltiel, 2001). This
process leads to an increase of insulin releasing by beta cells
in the pancreas, as compensatory mechanism to maintain
glucose homeostasis. However, maintenance of this
increased insulin production in time, generates a relative
deficiency in the releasing of the hormone from pancreatic
beta cells, leading to impaired glucose tolerance (Lebovitz
& Banerji, 2004). However, the relative deficiency in insulin
secretion is generally a late process in the whole pathogenic
scenario, being a characteristic of a frank diabetic state.
Both environmental and genetic factors had been
largely associated with the establishment  of T2DM (Jenkins
& Campbell, 2004), and jointly contributing to the apparition
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SUMMARY: Type 2 diabetes mellitus implies deregulation of multiple metabolic processes, being the maintenance of glycemia
one of the most important. Many genes are involved in the deregulation of this particular process. Therefore, the aim of this study was to
evaluate gene expression of genes related to type 2 diabetes mellitus, in the liver and pancreas of rats with hyperglycemia induced by
high fat diet along with a low single dose of streptozotocin.  Ahsg and Ppargc1a genes were studied in liver, whereas Kcnj11 and Slc2a2
genes were analyzed in pancreas. For this purpose, 210-240 g female rats were fed a high fat diet or a control diet for three weeks. At day
14, animals fed with high fat diet were injected with a single low dose of streptozotocin (35 mg/kg) and the control group rats were
injected only with the vehicle. Plasmatic glucose, triglycerides and total cholesterol levels were measured at the beginning, day 14 and
end of treatment. Body weight was also measured. Once the treatment was complete, rats were appropriately euthanized and then,
pancreas and liver were surgically removed and frozen in liquid nitrogen. Total RNA was isolated using TRIzol reagent, treated with
DNase I and reversely transcribed to cDNA. Gene expression analysis was performed using SYBR Green – Real time PCR and comparative
Cq method, using three reference genes. Rats fed with high fat diet and treated with streptozotocin showed higher values of plasmatic
glucose (17.09 ± 0.43 vs. 5.91 ± 0.29 mmol/L, p < 0.01) and a minor expression of Ppargc1a versus the control group (2-fold less
expressed, p < 0.05) in liver.  We conclude that repression of Ppargc1a gene may be an important process in the establishment of chronic
hyperglycemia, probably through deregulation of hepatic gluconeogenesis. However, further studies need to be performed in order to
clarify the role of Ppargc1a deregulation in liver glucose homeostasis.
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of abnormalities in glucose homeostasis. Sedentarism,
obesity and diet are the most recognized environmental risk
factors (Barroso et al., 2003; Cuevas-Alvarez et al., 2006;
Cuevas et al., 2009; Chan et al., 1994; Dowse et al., 1991;
Mokdad et al., 2001; Neuhouser et al., 2002; Sohet et al.,
2009). On the other hand, the heritable genetic component
has also been identified as risk factor of T2DM. From an
ethiopatogenic point of view, the high impact of
environmental factors and the polygenic character of T2DM
are two of the principal differences versus the monogenic
character and the relatively poor role of environmental
factors in type 1 diabetes mellitus.
Despite the fact that most of studies relating genetic
factors and T2DM are based in genetic variations
(polymorphisms), other molecular factors can act not only
in the establishment of the disease, but also in the
maintenance and deterioration of its metabolic and
physiologic features. In this way, despite the fact that
relatively limited attention has been put at gene regulation
level in T2DM, differences in gene expression in some genes
related to metabolic pathways could affect not only glucose
homeostasis at a global level, but also at organ specific level,
probably due to differences in basal gene expression in each
singular tissue.
Thus, the aim of this study was to evaluate gene
expression of four literature-based candidate genes related
to glucose metabolism or diabetes, in pancreas and liver of
rats with hyperglycemia induced by high fat diet along with
a low single dose of streptozotocin. Alpha-2-HS-glycoprotein
(Ahsg) and Peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha (Ppargc1a) genes were analyzed
liver, whereas Solute carrier family 2 (facilitated glucose
transporter), member2 (Slc2a2) and Potassium inwardly
rectifying channel, subfamily J, member 11 (Kcnj11) were
studied in pancreas.
MATERIAL AND METHOD
Animals and Experimental design. Hyperglycemic rats
were developed based on a previously described protocol
(Srinivasan et al., 2005) with modifications. 210-240 g
female rats (7-9 weeks of age) obtained from the Central
Bioterium of Universidad de Chile, were housed in
polypropylene cages at 22 ± 2 °C on a 12:12 hours light:dark
inverted cycle at the Animal House of Universidad de La
Frontera. Animals had free access to water and a standard
rodent laboratory chow for one week prior to diet
manipulation, allowing adaptation of animals to the new
environment. After this period, animals were randomly
divided in two groups 5 animals each, and fed a high fat diet
(HFD; 58% fat, 13% protein, 29% carbohydrate) or a con-
trol diet (CD; 35% fat, 20% protein, 45% carbohydrate) for
three weeks. At day 14 of dietary manipulation, animals fed
with HFD were injected intraperitoneally with a single low
dose of streptozotocin (35 mg/kg), while rats in control group
were injected only with the vehicle (citrate buffer, pH 4.4).
Dietary manipulation continued for one more week. Body
weight, plasmatic glucose (PGL), triglycerides (PTG) and
total cholesterol (PTC) levels were measured at the
beginning, day 14, and at the end of treatment (day 22). Rats
with fasting plasmatic glucose higher of 16.0 mM were
considered hyperglycemic, for purposes of this study. The
experiments followed the Guide Principles for the Care and
Use of Animals based on the Helsinki Declaration and was
approved by our local ethics committee. An overview of
experimental design is showed in Figure 1.
Blood collection and biochemical measures. Blood
samples (~100 µL) were obtained at the beginning of dietary
intervention (day 0), prior to STZ injection (day 14) and at
the end of treatment (day 21), by puncture of caudal vein.
Plasmatic fraction was obtained by centrifugation (8 min at
3000 rpm) and assayed in triplicate for plasmatic glucose,
triglycerides and total cholesterol, using commercial kits
based on GOD-PAP, GPO-PAP and CHOD-PAP methods,
respectively (Human GmbH, Wiesbaden, Germany),
following the manufacturer indications.
Tissue Collection and RNA isolation. Pancreas and liver
were obtained from rats after 6 hours fasting. Animals were
euthanized using an intracardiac injection of 80 mg/kg of
sodium thiopental. Pancreas and liver were surgically re-
moved, immediately frozen in liquid nitrogen and stored at
-80 °C until processing. RNA was isolated from ~ 60 mg of
tissue, using TRIzol Reagent (Invitrogen, Carlsbad, CA,
USA), with some modifications. Previous to wash step, RNA
was precipitated for at least 1 hour at - 20 °C, in order to
obtain a greater quantity of RNA. The RNA pellet was
dissolved in 60 µL of nuclease free water, treated with DNase
I (Fermentas, Burlington, Canada) and quantified in
NanoDrop ND 1000 UV spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). RNA integrity was
assessed electrophoretically in denaturing TAE agarose gels
(28S/18S rRNA ratio ≥ 2) and the purity was verified using
OD260/OD280 nm absorption ratio > 1.8 and OD260/
OD230 nm absorption ratio > 2.0.
Reverse transcription and Real-time PCR. For expression
analysis of Ahsg and Ppargc1a genes in liver, as well as
Slc2a2 and Kcnj11 in pancreas, DNase treated RNA from
corresponding tissue (1 µg) was reverse transcribed to cDNA
using M-MULV Reverse Transcriptase (Fermentas),
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following the manufacturer’s indications. For real-time PCR,
all samples were run in triplicate. PCR Reaction mix (20
µL) contained 200 ng of cDNA, 100 mM of specific forward
and reverse primers and 1x Fast SYBR Green Master Mix
(Applied Biosystems, Foster City, California, USA). The
primers used are detailed in Table I. All primers were
designed using Primer-BLAST tool of the National Center
for Biotechnology Information (http://www.ncbi.nlm.
nih.gov/tools/primer-blast/). The cycling was performed in
a Stratagene Mx3000 QPCR System (Agilent Technologies,
Santa Clara, California, USA) with an initial Polymerase
activation step of 95 °C for 10 min, followed by 40 cycles
of 95° C for 15 s, 55 °C for 30 s, and 72 °C for 30 s. A
dissociation curve was performed at the end of the run, in
order to check the quality of primers. Three genes were also
run as potential reference genes, analyzing their stabilities
with the geNorm tool (Vandesompele et al., 2002). The
reaction efficiencies were analyzed using a calibration
dilution curve, for each gene (Pfaffl, 2001) and the fold
change expression analysis was performed using the
comparative Cq method (2-DDCq).
Statistical analysis. All results are presented as Mean ±
S.E.M. Datasets were submitted to Kolmogorov-Smirnoff
normality test. If datasets passed the test, unpaired t test was
used to analyzing data between two groups or one-way
ANOVA and Tukey's post test, for multiple groups
comparisons. If dataset did not shown a Gaussian
distribution, Mann-Whitney test was used to compare two
groups or Kruskal-Wallis test with Dunns's test as multiple
comparison test.  A value of P < 0.05 was considered
statistically significant.
Fig. 1.Overview of experimental design of the study.
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RESULTS
Phenotypic characteristics of animals. Characteristics of
rats in Control and HFD + STZ groups are shown in Table
II. Animals did not show significant differences in body
weight, Plasmatic Glucose (PGL), Triglycerides (PTG) nor
Total Cholesterol (PTC), between control and HFD + STZ
group at the beginning of dietary manipulation. After two
weeks of diet administration and previous to administration
of STZ or vehicle, animals were weighted and blood samples
were taken again. Levels of PTG and PTC showed a
significant increase compared with values at beginning of
treatment in the HFD + STZ compared to control group while
PGL and body weight did not show differences. At the end
of the third week of dietary treatment (day 21), rats were
evaluated again, showing a significant increment in
concentration of PGL (p < 0.001), so long as the differences
in PTG and PTC remain significant (p < 0.01 and p < 0.001
respectively). Body weight did not show differences between
Control and HFD + STZ at any time point measured.
Real time PCR reaction quality control. All samples
yielded considerable amounts of RNA, over 100 µg/mL,
whereas 260/280 nm and 260/230 nm indexes were higher to
1.8 and 2.0 respectively, indicating acceptable purity of
isolated RNA. The efficiency of real time PCR reactions was
near to 100%, for all analyzed genes. The absence of multiple
peaks in dissociation curve denoted no primer dimers
formation and no non-specific amplification (data not shown).
Gene expression analyses. After verifying the quality of
real time PCR reaction, relative expression of mRNA for
the interest genes was performed. The analysis of reference
genes stability for these three genes showed that in pancreas
the most stable genes were Pgk1 and Rpl13a (M-value =
0.09), whereas Rpn1 and Pgk1a were the most stable pair in
liver (M-value = 0.11). Relative expression level of interest
genes were calculated with 2-DDCq formula using the Cq
geometric mean of reference genes above mentioned. Gene
Gene Gene Bank AccessN °° °° Primer Sequence
Ribophorin I (Rpn1)
NM_013067.1 Rpn1FRpn1R
CAACCTAGAAGTACGAGAAACC
TGAGTCGGGTATGGATGAAG
Phosphoglycerate kinase1 (Pgk1a) NM_053291.3 Pgk1aFPgk1aR
ACTGTGGCCTCTGGTATAC
CCCATTCAAATACCCCAACAG
Ribosomal protein L13A(Rpl13a)
NM_173340.2 Rpl13aFRpl13aR
GCAAAGATCCATTACCGGAAG
ACAGTCTTTATTGGGTTCACAC
Solute carrier family 2(facilitated glucose
transporter), member 2(Slc2a2) NM_012879.2
Slc2a2F
Slc2a2R
AGCCCCAGATACCTTTACC
CAGTGCCCCTTAGTCTTTTC
Potassium inwardly rectifying channel,
subfamily J, member 11 (Kcnj11) NM_031358.3
Kcnj11F
Kcnj11R
GCCAAGCCCAAGTTTAGC
CCCAGCACTCTACATACCGG
Alpha-2-HS-glycoprotein (Ahsg) NM_012898.4 AhsgFAhsgR
GGTCCACACTGTCAAAACTG
GCTATCACAAACTCCACGAG
Peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha (PGC-1) NM_031347.1
Pgc1aF
Pgc1aR
CCCACAGAGAACAGAAACAG
GGGTCAGAGGAAGAGATAAAG
Table I. Primer sequences of used for gene quantification in Real-time PCR experiments.
Day 0 Day 14 Day 21
Control HFD + STZ Control HFD + STZ Control HFD + STZ
Body weight (g) 249.7 –  3.54 237.8 –   2.95 259.6 –  1.54 255.80 –  0.86 271.00 –  2.77 272.0 –  2.24
PGL (mmol/L) 5.30 –  0.10 5.33 –  0.17 7.28 –  0.48 7.65 –  0.48 5.91 –  0.29 17.09 –  0.43***
PTG (mmol/L) 4.38 –  0.22 4.61 –  0.30 4.38 –  0.14 5.93 –  0.10 *** 3.76 –  0.20 8.71 –  1.22 **
PTC (mmol/L) 1.67 –  0.03 1.67 –  0.08 1.26 –  0.11 3.28 –  0.18 *** 1.71 –  0.04 3.43 –  0.17 ***
Table II. Characteristics of Control and HFD + STZ rats at the beginning of dietary treatment (day 0), before STZ or Vehicle injection
(day 14) and at the end of treatment (day 21).
Values are expressed as Mean ± S.E.M. The abbreviations denote PGL: Plasmatic Glucose, PGT: Plasmatic Triglycerides, PTC: Plasmatic Total Cholesterol.
**p < 0.01 vs. Control group. ***p < 0.001 vs. Control group. n = 5 per group.
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expression results for each tissue are shown in Figure 2. Of
all studied genes, only Ppargc1a showed a significant
reduction in gene expression in liver of hyperglycemic HFD
+ STZ group (2-fold less expressed, p < 0.05), whereas in
pancreas neither Slc2a2 nor Kcnj11 showed significant
differences.
DISCUSSION
The principal aim of the present study was to
investigate the expression of some diabetes-related genes in
pancreas and liver of rats with induced hyperglycemia. First
of all, a model of hyperglycemic like type 2 diabetic rats
were developed. To achieve this aim, we based our work on
previously the described model (Srinivasan et al., 2005),
with the differences that female Wistar rats were used instead
of male Sprague-Dawley rats and animals were fed with a
different diet, but always keeping the character of a high fat
diet. This model has two principal advantages. First, the
induced metabolic state of animals emulates metabolic
features of subjects with advanced type 2 diabetic state. The
high fat diet induce an increase of insulin resistance in target
tissues, whereas the low dose of STZ induce the decrease of
insulin release by the beta pancreas, both characteristics
present in advanced type 2 diabetic subjects. Despite the
fact that STZ is mostly used for Type 1 diabetes mellitus
due to its capacity of induce destruction of beta pancreatic
cells causing almost complete lack of insulin when is
administrated in high (> 65 mg/Kg) or multiple low doses,
is important to mention that this drug only generates partial
insulin deficiency when is administrated as a single low dose
(35 - 40 mg/Kg). The second advantage is the short time in
which the animals achieve a diabetic state, in contrast with
Fig. 2. Relative mRNA expression of the studied genes. A. Genes studied in pancreas. No differences were found in
expression levels of Slc2a2 and Kcnj11 genes. B. Genes studied in liver. Only Ppargc1a showed differences in gene
expression when compared HFD + STZ vs. Control group. Ashg remains unaltered.  * P < 0.05.
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protocols based only in dietary manipulation. In our study,
all animals treated with HFD and STZ generate non-fasting
hyperglycemias greater to 16.0 mmol/L (290 mg/dL), at the
end of treatment, in contrast with rats in control group, which
maintain normal glycemia (5.91 ± 0.29 mmol/L, p < 0.001).
However, due to technical restrictions, it was impossible to
evaluate insulin metabolism of studied animals. Therefore,
is not possible to ensure a real development of T2DM in the
animals, but only a hyperglycemic state. However, levels of
PGL founded in treated animals, suggest a real diabetic state
with partial deficiency of insulin, because the glycemias were
considerably higher compared with control group but not so
high as those found in type 1 diabetic animals.
After characterization of animals and confirmation
of the diabetic-like hyperglycemic state, gene expression
analysis was performed in liver and pancreas. Selection of
reference genes was based on the work of Cai et al. (2007),
whom evaluate gene expression of 48 genes in various rat
tissues, showing that genes encoding ribosomal proteins and
some enzymes related to energetic metabolism processes
were the most stables. Therefore, the selected references
genes were Pgk1, Rpl13a and Rpn1, for both, liver and
pancreas. In pancreas, two genes were studied. Slc2a2
(GLUT2) is the member 2 of solute carrier family 2
(facilitated glucose transporter). In pancreas, it mediates the
uptake glucose, process that initiate the glucose-stimulated
insulin secretion (Thorens, 2001). Previous studies have
associated polymorphisms of Slc2a2 gene with T2DM in
humans (Barroso et al., 2003; Kilpelainen et al., 2007). In
our study, animals in HFD + STZ animals showed a slight
increment in gene expression of Slc2a2, but no statistical
difference was found.
The second gene studied in pancreas was the
Potassium inwardly rectifying channel, subfamily J, member
11 (Kcnj11). This gene encode for the subunit Kir6.2 of the
ATP-sensitive potassium channel (KATP), which is involved
in membrane depolarization needed for insulin releasing
from pancreatic beta cells (Patch et al., 2007).
Polymorphisms of this gene have been found in Type 2
diabetic patients from some ethnic populations (Gong et al.,
2011; Yang et al., 2012), turning it as a candidate gene for
T2DM. A low expression of this gene could contribute to
hyperglycemia, causing lower insulin releasing from beta
cells. In our study, no difference was found in gene
expression of Kcnj11 gene. However, as in the case of Slc2a2,
there is a trend to increased mRNA expression of Kcnj11 in
HFD + STZ group. The slight increase in expression levels
of these genes could be acting like a compensatory
mechanism in response to hyperglycemia present in animals
of treated group, in order to increase the insulin releasing
from beta pancreatic cells.
On the other hand, Alpha-2-HS-glycoprotein (Ahsg)
and Peroxisome proliferators-activated receptor gamma,
coactivator 1 alpha (Ppargc1a) genes were analyzed in liver
of Control and hyperglycemic rats. Ahsg is a glycoprotein
secreted by liver and its principal role is in biomineralization
of bone, but also in regulation of insulin signaling. When
this function is deregulated, impaired glucose disposal and
fatty liver could occur (Goustin & Abou-Samra, 2011). No
differences were detected in gene expression of Ahsg,
between Control and DAG + STZ group.
Ppargc1a is involved in energetic metabolism,
interacting with multiple transcription factors through
PPARG. In our study, Ppargc1a showed a significant
reduction in gene expression of about 40% in hyperglycemic
animals, when compared with normoglycemic animals. The
liver is the principal producer of glucose (through
glycogenolysis or gluconeogenesis ways), and Ppargc1a is
an important modulator of metabolic activity in this organ,
being involved in processes like gluconeogenesis and fatty
acid b-oxidation (Liu & Lin, 2011). When Ppargc1 is induced,
it will coactivateFoxO1 and Hnf4a, increasing transcription
of gluconeogenic genes such as Pck1 and G6Pase (Rodgers
et al., 2008). Thus, a lower expression of Ppargc1a will redu-
ce gluconeogenic rate and consequently the release of glucose
by the liver. Therefore, the reduction in mRNA levels of
Ppargc1a found in HFD + STZ animals could be a
compensatory mechanism against hyperglycemia, minimizing
the generation and liberation of glucose by liver. In addition,
lack of insulin in animals of HFD + STZ group, could alter
other co-activators regulated for this hormone involved in
gluconeogenic pathway like FoxO1 and Hnf4a, through Akt
modulation, possibly affecting the Ppargc1a activity as well.
In summary, in liver of hyperglycemic rats, decreased gene
expression levels of Ppargc1a were found, when compared
to the control group. Ppargc1a is an important metabolic
regulator in the liver. Decrease of Ppargc1a gene expression
could act as a compensatory mechanism to hyperglycemia,
reducing gluconeogenesis and consequently glucose release
from liver. However, further studies need to be performed in
order to clarify the role of Ppargc1a deregulation in liver
glucose homeostasis, in this animal model.
HERNANDEZ, A.; CURI, R. & SALAZAR, L. A. Represión
del gen Ppargc1a en hígado de ratas con hiperglicemia inducida
por dieta alta en grasas combinada con estreptozotocina. Int. J.
Morphol., 30(2):643-650, 2012.
RESUMEN: La diabetes mellitus tipo 2 implica
desregulación de varios procesos metabólicos, siendo la manten-
ción de la glicemia uno de los más importantes. Varios genes es-
tán involucrados en este proceso. Así, el objetivo del presente
estudio fue evaluar la expresión génica de genes relacionados a
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diabetes mellitus tipo 2 en hígado y páncreas de ratas con
hiperglicemia inducida con una dieta alta en grasas junto con una
baja dosis de estreptozotocina. Ratas hembra de 210 - 240 g fue-
ron alimentadas con una dieta alta en grasas o con una dieta con-
trol por tres semanas. Al día 14, los animales alimentados con
dieta alta en grasas fueron inyectados con una dosis baja de
estreptozotocina (35 mg/kg), mientras las del grupo control fue-
ron inyectadas con el vehículo. El peso corporal y las concentra-
ciones plasmáticas de glucosa, triglicéridos y colesterol total, fue-
ron medidos al inicio, al día 14 y al final del tratamiento. Al fina-
lizar el tratamiento, los animales fueron sacrificados, el hígado y
páncreas fueron quirúrgicamente removidos e inmediatamente
congelados en nitrógeno liquido. El RNA fue extraído usando el
reactivo TRIzol, tratado con DNasa I y posteriormente converti-
do a cDNA. Los análisis de expresión génica fueron realizados
usando SYBR Green - real time PCR y el método del Cq compa-
rativo. En hígado se estudiaron los genes Ahsg y Ppargc1a, mien-
tras que en páncreas se analizaron los genes Slc2a2 y Kcnj11.
Las ratas alimentadas con dieta alta en grasas y tratadas con
streptozotocina mostraron niveles mayores de glucosa plasmática
(17,09 ± 0,43 vs. 5,91 ± 0,29 mmol/L, p < 0,01) y una menor
expresión hepática de Ppargc1a versus el grupo control (2 veces
menor expresión, p < 0,05). En conclusión, la represión del gen
Ppargc1a puede ser un importante proceso en el establecimiento
de la hiperglicemia crónica, probablemente debido a una
desregulación de la gluconeogénesis hepática. Sin embargo, es-
tudios adicionales son necesarios para esclarecer el rol de esta
desregulación en la homeostasis hepática de glucosa.
PALABRAS CLAVE: Expresión génica;
Hiperglicemia; Ppargc1a.
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